R
Robert A. Krance
Researcher at Baylor College of Medicine
Publications - 78
Citations - 5257
Robert A. Krance is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Hematopoietic stem cell transplantation & Transplantation. The author has an hindex of 27, co-authored 78 publications receiving 4684 citations. Previous affiliations of Robert A. Krance include University of Tennessee Health Science Center & Center for Cell and Gene Therapy.
Papers
More filters
Journal ArticleDOI
Inducible apoptosis as a safety switch for adoptive cell therapy
Antonio Di Stasi,Siok-Keen Tey,Gianpietro Dotti,Yuriko Fujita,Alana A. Kennedy-Nasser,Caridad Martinez,Karin Straathof,Enli Liu,April G. Durett,Bambi Grilley,Hao Liu,Conrad Russell Y. Cruz,Barbara Savoldo,Adrian P. Gee,John Schindler,Robert A. Krance,Helen E. Heslop,David M. Spencer,Cliona M. Rooney,Malcolm K. Brenner +19 more
TL;DR: The inducible T-cell safety switch based on the fusion of human caspase 9 to a modified human FK-binding protein, allowing conditional dimerization may increase the safety of cellular therapies and expand their clinical applications.
Journal ArticleDOI
Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial
Amar Gajjar,Murali Chintagumpala,David M. Ashley,Stewart J. Kellie,Larry E. Kun,Thomas E. Merchant,S.Y. Woo,Greg Wheeler,Valerie Ahern,Matthew J. Krasin,Maryam Fouladi,Alberto Broniscer,Robert A. Krance,Gregory A. Hale,Clinton F. Stewart,Robert C. Dauser,Robert A. Sanford,Christine E. Fuller,Ching C. Lau,James M. Boyett,Dana Wallace,Richard J. Gilbertson +21 more
TL;DR: Investigating the effectiveness of risk-adapted radiotherapy followed by a shortened period of dose-intense chemotherapy in children with medulloblastoma found it can be used to improve the outcome of patients with high-risk medullOBlastoma.
Journal ArticleDOI
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.
Ann M. Leen,G. Doug Myers,Uluhan Sili,M. Helen Huls,Heidi L. Weiss,Kathryn S. Leung,George Carrum,Robert A. Krance,Chung Che Chang,Jeffrey J. Molldrem,Adrian P. Gee,Malcolm K. Brenner,Helen E. Heslop,Cliona M. Rooney,Catherine M. Bollard +14 more
TL;DR: Genetic modification of antigen-presenting cell lines are described to facilitate the production of CD4+ and CD8+ T lymphocytes specific for CMV, EBV and several serotypes of adenovirus from a single cell culture.
Journal ArticleDOI
Prompt versus preemptive intervention for EBV lymphoproliferative disease.
Hans-Joachim Wagner,Yee Chung Cheng,Yee Chung Cheng,M. Helen Huls,M. Helen Huls,Adrian P. Gee,Adrian P. Gee,Ingrid Kuehnle,Ingrid Kuehnle,Robert A. Krance,Robert A. Krance,Malcolm K. Brenner,Cliona M. Rooney,Cliona M. Rooney,Helen E. Heslop,Helen E. Heslop +15 more
TL;DR: Quantitative measurement of EBV DNA may best be used to enable the prompt rather than the preemptive treatment of PTLD, and all patients were promptly and successfully treated with EBV-specific cytotoxic T cells or CD20 monoclonal antibody.
Journal ArticleDOI
Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory t cells without diminishing antiviral and antileukemic activity
Alana A. Kennedy-Nasser,Stephanie Ku,Paul Castillo-Caro,Yasmin Hazrat,Meng Fen Wu,Hao Liu,Jos Melenhorst,A. John Barrett,Sawa Ito,Aaron E. Foster,Barbara Savoldo,Eric Yvon,George Carrum,George Carrum,Carlos A. Ramos,Carlos A. Ramos,Robert A. Krance,Robert A. Krance,Kathryn S. Leung,Helen E. Heslop,Helen E. Heslop,Malcolm K. Brenner,Malcolm K. Brenner,Catherine M. Bollard,Catherine M. Bollard +24 more
TL;DR: ULD IL-2 is well tolerated, expands a Treg population in vivo, and may be associated with a lower incidence of viral infections and GVHD.